Zenas BioPharma, Inc.
Close on Oct 19, 2026
- Market cap
- $1.69B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $1.00M | $-1.77 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-1.46 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | Before market open | – | $-4.54 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-1.22 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | $-1.25 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $10.00M | $-0.80 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 5, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
Press releases
Announcements Zenas BioPharma filed with the SEC
BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · Shareholder vote results · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zenas BioPharma Reports Third Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Zenas BioPharma Announces Positive Results from
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
about Zenas BioPharma, Inc. and its consolidated subsidiaries. You also should read and consider the information contained in other reports
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Zenas BioPharma and Royalty Pharma Enter into
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Zenas BioPharma Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Zenas BioPharma Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Zenas BioPharma Announces Key 2024 Accomplishments
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K